…it would probably be possible for SNY to launch a generic without violating [MNTA’s Lovenox patents]
SNY’s authorized generic (should they choose to launch one) would in all likelihood be simply branded Lovenox with different packaging, so MNTA’s patents would not be in play.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”